To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose
Timeframe: Up to 24 hours post dose
Number of Participants With AEs Within 14 Days Post Any Dose
Timeframe: Up to 14 days post dose
Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post Dose
Timeframe: Up to 24 hours post dose
Number of Participants Discontinued From Study Due to AEs Occurring Within 14 Days Post Dose
Timeframe: Up to 14 days post dose